Transgene SA (EPA:TNG)

Market Cap	87.91M
Revenue (ttm)	6.35M
Net Income (ttm)	-33.97M
Shares Out	131.99M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,817
Average Volume	30,658
Open	0.6840
Previous Close	0.6710
Day's Range	0.6710 - 0.6840
52-Week Range	0.6560 - 1.5200
Beta	0.79
RSI	39.78
Earnings Date	Mar 27, 2025

About Transgene

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1979
• Employees: 141
• Stock Exchange: Euronext Paris
• Ticker Symbol: TNG

Financial Performance

In 2024, Transgene's revenue was 6.35 million, a decrease of -19.58% compared to the previous year's 7.90 million. Losses were -33.97 million, 52.1% more than in 2023.